Merck & Co., Inc.(MRK)Earnings, Financials & Key Ratios

MRK•NYSE

$113.16

$279.49B mkt cap·15.5× P/E·Price updated May 6, 2026

SectorHealthcare IndustryLarge Pharma Sub-IndustryVaccines and plasma-derived therapies

AboutMerck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.Show more

Revenue$64.93B+1.2%
EBITDA$29.32B+18.6%
Net Income$18.25B+6.6%
EPS (Diluted)7.28+8.0%
Gross Margin71.98%-5.7%
EBITDA Margin45.17%+17.2%
Operating Margin36.17%+14.8%
Net Margin28.12%+5.4%
ROE36.86%-9.5%
ROIC22.01%+0.5%
Debt/Equity0.96+16.3%
Interest Coverage17.31+3.7%

Analysis→Technical→

MRK Key Insights

Merck & Co., Inc. (MRK) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Excellent 3Y average ROE of 26.2%
✓Strong 5Y profit CAGR of 20.9%
✓FCF machine: 19.0% free cash flow margin
✓14 consecutive years of dividend growth
✓Healthy dividend yield of 2.9%
✓Healthy 5Y average net margin of 21.3%

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

MRK Price & Volume

Merck & Co., Inc. (MRK) stock price & volume — 10-year historical chart

Loading chart...

MRK Growth Metrics

Merck & Co., Inc. (MRK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years5.1%

5 Years9.35%

3 Years3.08%

TTM1.18%

Profit CAGR

10 Years15.18%

5 Years20.9%

3 Years7.93%

TTM6.64%

EPS CAGR

10 Years16.65%

5 Years21.23%

3 Years8.43%

TTM8.17%

Return on Capital

10 Years14.28%

5 Years18.24%

3 Years17.07%

Last Year23.82%

MRK Recent Earnings

Merck & Co., Inc. (MRK) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 11/12 qtrs (92%)●Beat Revenue 11/12 qtrs (92%)

Q2 2026Latest

Apr 30, 2026

EPS

$1.28

Est $1.47

+12.9%

Revenue

$16.3B

Est $15.8B

+2.8%

Q1 2026

Feb 3, 2026

EPS

$2.04

Est $2.01

+1.5%

Revenue

$16.4B

Est $16.2B

+1.2%

Q4 2025

Oct 30, 2025

EPS

$2.58

Est $2.36

+9.3%

Revenue

$17.3B

Est $17.0B

+1.8%

Q3 2025

Jul 29, 2025

EPS

$2.13

Est $2.03

+4.9%

Revenue

$15.8B

Est $15.9B

-0.4%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	Apr 30, 2026	$1.28vs $1.47+12.9%	$16.3Bvs $15.8B+2.8%
Q1 2026	Feb 3, 2026	$2.04vs $2.01+1.5%	$16.4Bvs $16.2B+1.2%
Q4 2025	Oct 30, 2025	$2.58vs $2.36+9.3%	$17.3Bvs $17.0B+1.8%
Q3 2025	Jul 29, 2025	$2.13vs $2.03+4.9%	$15.8Bvs $15.9B-0.4%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	FCF Yield	Debt / Equity
PFEPfizer Inc.Direct Competitor	150.4B	26.44	19.44	-1.65%	11.83%	8.34%	6.03%	0.78
LLYEli Lilly and CompanyDirect Competitor	933.66B	988.19	43.06	44.7%	34.98%	101.17%	0.96%	1.60
ABBVAbbVie Inc.Direct Competitor	364.63B	206.15	86.98	8.57%	6.91%	62.15%	4.89%
BMYBristol-Myers Squibb CompanyDirect Competitor	116.22B	56.92	16.50	-0.22%	15.01%	38.96%	11.05%	2.55
AMGNAmgen Inc.Direct Competitor	177.87B	329.59	23.16	9.92%	20.95%	89.41%	4.55%	6.31
JNJJohnson & JohnsonDirect Competitor	543.64B	225.59	38.96	4.3%	27.26%	31.69%	3.65%	0.51
AZNAstraZeneca PLCProduct Competitor	280.97B	181.24	27.71	8.63%	17.19%	22.24%	4.19%	0.61
GSKGSK plcProduct Competitor	101.32B	50.38	6.67	4.11%	19.19%	31.48%	7.81%	1.11

Compare MRK vs Peers

Merck & Co., Inc. (MRK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs PFE

Most directly comparable listed peer for MRK.

Scale Benchmark

vs LLY

Larger-name benchmark to compare MRK against a more recognizable public peer.

Peer Set

Compare Top 5

vs PFE, LLY, ABBV, BMY

MRK Income Statement

Merck & Co., Inc. (MRK) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Sales/Revenue	40.12B	42.29B	39.12B	41.52B	48.7B	59.28B	60.12B	64.17B	64.93B
Revenue Growth %	0.79%	5.41%	-7.5%	6.13%	17.31%	21.72%	1.4%	6.74%	1.18%
Cost of Goods Sold	12.91B	13.51B	12.02B	13.62B	13.63B	17.41B	16.13B	15.19B	18.2B
COGS % of Revenue	32.18%	31.94%	30.71%	32.8%	27.98%	29.37%	26.83%	23.68%	28.02%
Gross Profit	27.21B▲ 0%	28.79B▲ 5.8%	27.11B▼ 5.8%	27.9B▲ 2.9%	35.08B▲ 25.7%	41.87B▲ 19.4%	43.99B▲ 5.1%	48.98B▲ 11.3%	46.73B▼ 4.6%
Gross Margin %	67.82%	68.06%	69.28%	67.2%	72.02%	70.63%	73.17%	76.32%	71.98%
Gross Profit Growth %	5.56%	5.79%	-5.84%	2.93%	25.73%	19.37%	5.06%	11.33%	-4.58%
Operating Expenses	20.41B	19.85B	19.18B	22.35B	21.88B	23.59B	41.03B	28.75B	23.25B
OpEx % of Revenue	50.88%	46.94%	49.02%	53.84%	44.92%	39.79%	68.26%	44.81%	35.8%
Selling, General & Admin	10.07B	10.1B	9.46B	8.57B	9.4B	9.67B	9.88B	10.1B	10.73B
SG&A % of Revenue	25.11%	23.89%	24.17%	20.64%	19.31%	16.31%	16.44%	15.74%	16.53%
Research & Development	10.34B	9.75B	9.72B	13.4B	12.24B	13.55B	30.53B	17.94B	12.51B
R&D % of Revenue	25.77%	23.06%	24.86%	32.27%	25.14%	22.85%	50.79%	27.95%	19.27%
Other Operating Expenses	0	0	0	386M	231M	373M	620M	716M	0
Operating Income	6.8B▲ 0%	8.93B▲ 31.4%	7.93B▼ 11.3%	5.55B▼ 30.0%	13.2B▲ 137.9%	18.28B▲ 38.5%	2.95B▼ 83.8%	20.22B▲ 584.5%	23.49B▲ 16.1%
Operating Margin %	16.94%	21.12%	20.26%	13.36%	27.1%	30.84%	4.91%	31.51%	36.17%
Operating Income Growth %	23.6%	31.4%	-11.25%	-30%	137.91%	38.51%	-83.84%	584.53%	16.15%
EBITDA	11.47B	13.45B	11.24B	9.03B	16.41B	22.19B	6.83B	24.72B	29.32B
EBITDA Margin %	28.6%	31.8%	28.72%	21.76%	33.7%	37.43%	11.35%	38.52%	45.17%
EBITDA Growth %	4.59%	17.23%	-16.46%	-19.6%	81.68%	35.2%	-69.24%	262.14%	18.62%
D&A (Non-Cash Add-back)	4.68B	4.52B	3.31B	3.49B	3.21B	3.91B	3.87B	4.5B	5.84B
EBIT	7.28B	9.47B	12.36B	6.69B	14.69B	17.41B	3.04B	21.21B	23.49B
Net Interest Income	-369M	-429M	-619M	-772M	-770M	-805M	-781M	-856M	-1.01B
Interest Income	385M	343M	274M	59M	36M	157M	365M	415M	343M
Interest Expense	754M	772M	893M	831M	806M	962M	1.15B	1.27B	1.36B
Other Income/Expense	-276M	-230M	-755M	315M	680M	-1.84B	-1.06B	-285M	-2.42B
Pretax Income	6.52B▲ 0%	8.7B▲ 33.4%	7.17B▼ 17.6%	5.86B▼ 18.2%	13.88B▲ 136.7%	16.44B▲ 18.5%	1.89B▼ 88.5%	19.94B▲ 955.4%	21.07B▲ 5.7%
Pretax Margin %	16.25%	20.57%	18.33%	14.12%	28.5%	27.74%	3.14%	31.07%	32.45%
Income Tax	4.1B	2.51B	1.56B	1.34B	1.52B	1.92B	1.51B	2.8B	2.8B
Effective Tax Rate %	62.92%	28.82%	21.82%	22.86%	10.96%	11.66%	80.04%	14.06%	13.31%
Net Income	2.39B▲ 0%	6.22B▲ 159.8%	9.84B▲ 58.2%	7.07B▼ 28.2%	13.05B▲ 84.6%	14.52B▲ 11.3%	365M▼ 97.5%	17.12B▲ 4589.6%	18.25B▲ 6.6%
Net Margin %	5.97%	14.71%	25.16%	17.02%	26.79%	24.49%	0.61%	26.68%	28.12%
Net Income Growth %	-38.93%	159.82%	58.25%	-28.2%	84.65%	11.27%	-97.49%	4589.59%	6.64%
Net Income (Continuing)	2.42B	6.19B	5.61B	4.52B	12.36B	14.53B	377M	17.13B	18.26B
Discontinued Operations	0	0	4.15B	2.55B	704M	0	0	0	0
Minority Interest	233M	181M	94M	87M	73M	67M	54M	59M	56M
EPS (Diluted)	0.93▲ 0%	2.32▲ 149.5%	3.82▲ 64.7%	2.78▼ 27.2%	5.14▲ 84.9%	5.71▲ 11.1%	0.14▼ 97.5%	6.74▲ 4714.3%	7.28▲ 8.0%
EPS Growth %	-54.41%	149.46%	64.66%	-27.23%	84.89%	11.09%	-97.55%	4714.29%	8.01%
EPS (Basic)	0.95	2.40	3.84	2.79	5.16	5.73	0.14	6.76	7.30
Diluted Shares Outstanding	2.75B	2.68B	2.58B	2.54B	2.54B	2.54B	2.55B	2.54B	2.51B
Basic Shares Outstanding	2.7B	2.59B	2.56B	2.53B	2.53B	2.53B	2.61B	2.53B	2.5B
Dividend Payout Ratio	215.83%	83.15%	57.86%	87.94%	50.66%	48.3%	2039.73%	45.8%	44.79%

MRK Balance Sheet

Merck & Co., Inc. (MRK) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Total Current Assets	24.77B	25.88B	27.48B	27.76B	30.27B	35.72B	32.17B	38.78B	43.52B
Cash & Short-Term Investments	8.5B	8.86B	10.45B	8.05B	8.1B	13.19B	7.09B	13.69B	14.56B
Cash Only	6.09B	7.96B	9.68B	8.05B	8.1B	12.69B	6.84B	13.24B	14.56B
Short-Term Investments	2.41B	899M	774M	0	0	498M	252M	447M	0
Accounts Receivable	6.87B	7.07B	6.78B	6.8B	9.23B	9.45B	10.35B	10.28B	12.68B
Days Sales Outstanding	62.53	61.02	63.24	59.81	69.17	58.18	62.84	58.46	71.28
Inventory	5.1B	5.44B	5.98B	5.55B	5.95B	5.91B	6.36B	6.11B	6.66B
Days Inventory Outstanding	144.06	146.98	181.59	148.86	159.46	123.92	143.91	146.76	133.56
Other Current Assets	4.3B	4.5B	4.28B	7.36B	6.99B	7.17B	8.37B	8.71B	9.49B
Total Non-Current Assets	63.11B	56.76B	56.91B	63.82B	75.43B	73.44B	74.51B	78.32B	93.35B
Property, Plant & Equipment	12.44B	13.29B	15.05B	17B	19.28B	21.42B	23.05B	23.78B	26.82B
Fixed Asset Turnover	3.23x	3.18x	2.60x	2.44x	2.53x	2.77x	2.61x	2.70x	2.42x
Goodwill	18.28B	18.25B	19.43B	18.88B	21.26B	21.2B	21.2B	21.67B	21.58B
Intangible Assets	14.18B	13.1B	14.2B	14.1B	22.93B	20.27B	18.01B	16.37B	26.68B
Long-Term Investments	12.13B	6.23B	1.47B	785M	370M	1.01B	252M	463M	2.24B
Other Non-Current Assets	6.08B	5.88B	6.77B	13.06B	11.58B	9.53B	12B	16.04B	16.03B
Total Assets	87.87B▲ 0%	82.64B▼ 6.0%	84.4B▲ 2.1%	91.59B▲ 8.5%	105.69B▲ 15.4%	109.16B▲ 3.3%	106.67B▼ 2.3%	117.11B▲ 9.8%	136.87B▲ 16.9%
Asset Turnover	0.46x	0.51x	0.46x	0.45x	0.46x	0.54x	0.56x	0.55x	0.47x
Asset Growth %	-7.87%	-5.96%	2.13%	8.52%	15.4%	3.28%	-2.28%	9.78%	16.87%
Total Current Liabilities	18.61B	22.21B	22.22B	27.33B	23.87B	24.24B	25.69B	28.42B	28.33B
Accounts Payable	3.1B	3.32B	3.74B	4.33B	4.61B	4.26B	3.92B	4.08B	4.4B
Days Payables Outstanding	87.69	89.65	113.55	115.98	123.46	89.39	88.77	97.99	88.35
Short-Term Debt	3.06B	5.31B	3.61B	6.43B	2.41B	1.95B	1.37B	2.65B	2.88B
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	795M	-304M	-281M	-285M	-282M	14.09B
Current Ratio	1.33x	1.17x	1.24x	1.02x	1.27x	1.47x	1.25x	1.36x	1.54x
Quick Ratio	1.06x	0.92x	0.97x	0.81x	1.02x	1.23x	1.00x	1.15x	1.30x
Cash Conversion Cycle	118.89	118.36	131.28	92.69	105.17	92.71	117.97	107.23	116.49
Total Non-Current Liabilities	34.69B	33.55B	36.18B	38.86B	43.56B	38.86B	43.35B	42.31B	55.88B
Long-Term Debt	21.35B	19.81B	22.74B	25.36B	30.69B	28.75B	33.68B	34.46B	46.75B
Capital Lease Obligations	0	0	768M	1.33B	1.23B	1.01B	928M	877M	901M
Deferred Tax Liabilities	2.22B	1.7B	1.47B	1B	3.44B	1.79B	871M	1.39B	1.44B
Other Non-Current Liabilities	11.12B	12.04B	11.2B	11.16B	8.21B	7.31B	7.86B	5.59B	6.79B
Total Liabilities	53.3B	55.76B	58.4B	66.18B	67.44B	63.1B	69.04B	70.73B	84.2B
Total Debt	24.41B	25.11B	27.35B	33.42B	34.63B	31.98B	36.27B	38.27B	50.53B
Net Debt	18.32B	17.15B	17.68B	25.37B	26.54B	19.29B	29.43B	25.03B	35.97B
Debt / Equity	0.71x	0.93x	1.05x	1.32x	0.91x	0.69x	0.96x	0.83x	0.96x
Debt / EBITDA	2.13x	1.87x	2.43x	3.70x	2.11x	1.44x	5.31x	1.55x	1.72x
Net Debt / EBITDA	1.60x	1.28x	1.57x	2.81x	1.62x	0.87x	4.31x	1.01x	1.23x
Interest Coverage	9.65x	12.27x	13.84x	8.06x	18.22x	18.09x	2.65x	16.69x	17.31x
Total Equity	34.57B▲ 0%	26.88B▼ 22.2%	26B▼ 3.3%	25.4B▼ 2.3%	38.26B▲ 50.6%	46.06B▲ 20.4%	37.63B▼ 18.3%	46.37B▲ 23.2%	52.66B▲ 13.6%
Equity Growth %	-14.24%	-22.24%	-3.28%	-2.3%	50.59%	20.39%	-18.29%	23.22%	13.56%
Book Value per Share	12.58	10.03	10.08	10.00	15.07	18.12	14.78	18.25	21.01
Total Shareholders' Equity	34.34B	26.7B	25.91B	25.32B	38.18B	45.99B	37.58B	46.31B	52.61B
Common Stock	1.79B	1.79B	1.79B	1.79B	1.79B	1.79B	1.79B	1.79B	1.79B
Retained Earnings	41.35B	42.58B	46.6B	47.36B	53.7B	61.08B	53.9B	63.07B	73.08B
Treasury Stock	-43.79B	-50.93B	-55.95B	-56.79B	-57.11B	-56.49B	-57.45B	-58.3B	-63B
Accumulated OCI	-4.91B	-5.54B	-6.19B	-6.63B	-4.43B	-4.77B	-5.16B	-4.95B	-4.29B
Minority Interest	233M	181M	94M	87M	73M	67M	54M	59M	56M

MRK Cash Flow Statement

Merck & Co., Inc. (MRK) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Cash from Operations	6.45B	10.92B	13.44B	10.25B	14.11B	19.09B	13.01B	21.47B	16.47B
Operating CF Margin %	16.07%	25.82%	34.36%	24.7%	28.97%	32.21%	21.64%	33.46%	25.37%
Operating CF Growth %	-37.87%	69.41%	23.05%	-23.71%	37.61%	35.34%	-31.89%	65.06%	-23.27%
Net Income	2.42B	6.19B	9.78B	7.08B	12.36B	14.53B	365M	17.13B	18.25B
Depreciation & Amortization	4.64B	4.52B	3.65B	3.63B	3.21B	3.91B	3.87B	4.5B	5.84B
Stock-Based Compensation	312M	348M	417M	441M	479M	541M	645M	761M	0
Deferred Taxes	-2.62B	-509M	-556M	-668M	187M	-1.57B	-1.9B	-1.25B	-1.67B
Other Non-Cash Items	6.72B	1.92B	2.22B	4.36B	1.71B	4.47B	12.23B	3.99B	1.03B
Working Capital Changes	-5.02B	-1.55B	-2.07B	-4.59B	-3.84B	-2.78B	-2.21B	-3.67B	-6.98B
Change in Receivables	297M	-418M	294M	-1B	-2.03B	-644M	-1.15B	-244M	-1.09B
Change in Inventory	-145M	-911M	-508M	-855M	-674M	-161M	-816M	-835M	-1.18B
Change in Payables	254M	230M	399M	724M	405M	-289M	-380M	182M	110M
Cash from Investing	2.68B	4.31B	-2.63B	-9.44B	-16.55B	-4.96B	-14.08B	-7.73B	-13.74B
Capital Expenditures	-1.89B	-2.62B	-3.47B	-4.68B	-4.45B	-4.39B	-3.86B	-3.37B	-4.11B
CapEx % of Revenue	4.71%	6.18%	8.88%	11.28%	9.13%	7.4%	6.43%	5.25%	6.33%
Acquisitions	-396M	-431M	-4.95B	-6.61B	-12.91B	-121M	-12.03B	-4.09B	-10.04B
Investments	-	-	-	-	-	-	-	-	-
Other Investing	38M	102M	378M	130M	-225M	32M	1.11B	-127M	-58M
Cash from Financing	-10.01B	-13.16B	-8.86B	-2.83B	2.59B	-9.12B	-4.81B	-7.03B	-1.92B
Debt Issued (Net)	-1.13B	837M	1.25B	5.01B	1.63B	-2.25B	4.18B	2.31B	11.38B
Equity Issued (Net)	-4.01B	-9.09B	-4.78B	-1.28B	-840M	384M	-1.35B	-1.31B	-4.99B
Dividends Paid	-5.17B	-5.17B	-5.7B	-6.21B	-6.61B	-7.01B	-7.45B	-7.84B	-8.18B
Share Repurchases	-4.01B	-9.09B	-4.78B	-1.28B	-840M	0	-1.35B	-1.31B	-5.08B
Other Financing	304M	266M	366M	-347M	8.41B	-240M	-203M	-195M	-131M
Net Change in Cash	-423M▲ 0%	1.87B▲ 542.3%	1.97B▲ 5.1%	-1.77B▼ 189.9%	14M▲ 100.8%	4.61B▲ 32800.0%	-5.86B▼ 227.3%	6.41B▲ 209.3%	1.37B▼ 78.6%
Free Cash Flow	4.56B▲ 0%	8.31B▲ 82.1%	9.97B▲ 20.0%	5.82B▼ 41.6%	9.66B▲ 65.9%	14.71B▲ 52.2%	9.14B▼ 37.8%	18.1B▲ 97.9%	12.36B▼ 31.7%
FCF Margin %	11.37%	19.64%	25.48%	14.03%	19.84%	24.81%	15.21%	28.2%	19.04%
FCF Growth %	-47.92%	82.05%	19.98%	-41.57%	65.88%	52.23%	-37.83%	97.92%	-31.7%
FCF per Share	1.66	3.10	3.86	2.29	3.81	5.79	3.59	7.12	4.93
FCF Conversion (FCF/Net Income)	2.69x	1.76x	1.37x	1.45x	1.08x	1.32x	35.63x	1.25x	0.90x
Interest Paid	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0

MRK Key Ratios

Merck & Co., Inc. (MRK) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	9.22%	6.39%	20.24%	37.23%	27.5%	41%	34.44%	0.87%	40.75%	36.86%
Return on Invested Capital (ROIC)	6.8%	9.14%	13.82%	13.56%	8.81%	17.13%	21.07%	3.35%	21.91%	22.01%
Gross Margin	64.75%	67.82%	68.06%	69.28%	67.2%	72.02%	70.63%	73.17%	76.32%	71.98%
Net Margin	9.85%	5.97%	14.71%	25.16%	17.02%	26.79%	24.49%	0.61%	26.68%	28.12%
Debt / Equity	0.62x	0.71x	0.93x	1.05x	1.32x	0.91x	0.69x	0.96x	0.83x	0.96x
Interest Coverage	7.72x	9.65x	12.27x	13.84x	8.06x	18.22x	18.09x	2.65x	16.69x	17.31x
FCF Conversion	2.65x	2.69x	1.76x	1.37x	1.45x	1.08x	1.32x	35.63x	1.25x	0.90x
Revenue Growth	0.78%	0.79%	5.41%	-7.5%	6.13%	17.31%	21.72%	1.4%	6.74%	1.18%

MRK SEC Filings & Documents

Merck & Co., Inc. (MRK) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Apr 30, 2026·SEC

Material company update

Feb 3, 2026·SEC

Material company update

Dec 4, 2025·SEC

10-K Annual Reports

FY 2026

Feb 24, 2026·SEC

FY 2025

Feb 25, 2025·SEC

10-Q Quarterly Reports

FY 2025

Nov 5, 2025·SEC

FY 2025

Aug 5, 2025·SEC

FY 2025

May 2, 2025·SEC

MRK Frequently Asked Questions

Merck & Co., Inc. (MRK) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Merck & Co., Inc. (MRK) reported $64.93B in revenue for fiscal year 2025. This represents a 227% increase from $19.83B in 1996.

Merck & Co., Inc. (MRK) grew revenue by 1.2% over the past year. Growth has been modest.

Yes, Merck & Co., Inc. (MRK) is profitable, generating $18.25B in net income for fiscal year 2025 (28.1% net margin).

Dividend & Returns

Yes, Merck & Co., Inc. (MRK) pays a dividend with a yield of 2.88%. This makes it attractive for income-focused investors.

Merck & Co., Inc. (MRK) has a return on equity (ROE) of 36.9%. This is excellent, indicating efficient use of shareholder capital.

Merck & Co., Inc. (MRK) generated $12.36B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More MRK

Merck & Co., Inc. (MRK) financial analysis — history, returns, DCA and operating performance tools

Full MRK Stock Analysis

Analyst verdict, bull/bear case, risk factors and peer comparison

→

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Merck & Co., Inc.(MRK)Earnings, Financials & Key Ratios

MRK Key Insights

✓Strengths

✗Weaknesses

MRK Price & Volume

MRK Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

MRK Recent Earnings

MRK Peer Comparison

Compare MRK vs Peers

vs PFE

vs LLY

Compare Top 5

MRK Income Statement

MRK Balance Sheet

MRK Cash Flow Statement

MRK Key Ratios

MRK SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

MRK Frequently Asked Questions

Explore More MRK

Full MRK Stock Analysis

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation